Clinical trial · no report yet · Phase 2
Combi-TED
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
- NCT04884282 ↗
- Active, not recruiting
- Fondazione Ricerca Traslazionale
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Tedopi; Nivolumab; Docetaxel
- Arms
- Arm A - tedopi + docetaxel · Experimental
- Arm B - tedopi + nivolumab · Experimental
- Arm C - docetaxel · Other
- Enrollment
- 105 (estimated)
- Primary outcomes
- 1-year Survival Rate
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Oct 12, 2021
- Primary completion
- Sep 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04884282 · updated Feb 6, 2026
Publications
linked from the registry- Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Combi-TED: a new trial testing Tedopi(R) with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22. PubMed 36946237